Printer Friendly

Genetic Immunity Develops Unique Nanomedicine Formulation for DermaVir Therapeutic Vaccine for HIV/AIDS.

MCLEAN, Va. & BUDAPEST, Hungary -- Genetic Immunity, a multi-national biopharmaceutical company developing nanomedicine vaccines today announces publication of the Company's innovative work to develop a stable liquid formulation to deliver a novel nanomedicine. Appearing in the International Journal of Pharmaceutics, the paper addresses how Genetic Immunity was able to overcome significant hurdles facing the field to successfully formulate the first topically administered nanomedicine therapeutic vaccine for the treatment of HIV/AIDS, DermaVir.

"Biological activity of DermaVir depends upon its nanomedicine formulation that is essential for the potent expression of plasmid-DNA-encoded antigens. During Phase I and II clinical trials, DermaVir formulation required on-site admixture of three separate components followed by patient administration within three hours. We report here the development of a stable single liquid nanomedicine formulation, a significant milestone in developing DermaVir as a commercially viable global product to treat HIV/AIDS," commented Julianna Lisziewicz, PhD and CEO of Genetic Immunity.

Engineering novel nanomedicines presented Genetic Immunity with challenges not faced in the development of traditional biotechnology products. "One challenge in clinical nanomedicine development is to produce a stable formulation with reproducible manufacturing methods," explained Genetic Immunity's Eniko Toke, PhD. "We found several additional quality requirements of the components that were essential both to establish the optimal relationship between physicochemical properties and biological activity of DermaVir and to ensure reproducible manufacturing of a stable formulation. It became apparent that the current state-of-the-art approaches to sourcing, testing and manufacturing were insufficient."

Genetic Immunity implemented "Quality-by-Design" in biologic product development to manufacture a nanomedicine resulting in a new formulation of pDNA surrounded by a chemical polymer capable of maintaining the physical stability and biological activity of DermaVir at 4oC.

These discoveries will support DermaVir as it enters into Phase II/III human trials as a topically administered nanomedicine therapeutic vaccine. "Our Phase I trial demonstrated the preliminary safety and immunogenicity of DermaVir in HIV-positive people treated with HAART," Lisziewicz explained. "We have now also obtained Phase II data showing safety, immunogenicity and viral load reductions when DermaVir is used for initial treatment of HIV-infected individuals. This is the human proof of concept of our topical nanomedicine vaccine technology. It is our belief that DermaVir will become the first nanomedicine vaccine developed to reconstitute HIV-specific immunity with the potential to maintain the health of people living with HIV infection."

About Genetic Immunity

Genetic Immunity is a multinational biopharmaceutical company establishing leadership in nanomedicines for immune amplification. Nanomedicine employs nanotechnology science to deliver highly specific medical intervention on the molecular scale for treating disease. By leveraging its proprietary immune amplification platform technology, the Company addresses new markets for infectious diseases, cancer and allergies through the discovery, development and commercialization of topically administered nanomedicines to address significant unmet medical needs with the potential for alternative treatment approaches.
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1U5VA
Date:May 13, 2010
Words:461
Previous Article:Stage Stores Announces First Quarter Earnings Release Date and Conference Call Information.
Next Article:O'Charley's Inc. Reports Results for the First Quarter of 2010.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters